CClinicalTrials.gg
RecruitingNCT05910307Updated Jun 9, 2026

Synovial Sarcoma Registry / Biospecimen Repository

An observational study in Synovial Sarcoma, sponsored by Children's Hospital of Philadelphia. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Children's Hospital of Philadelphia · Observational

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
1,000
Sex
All
01

Study summary

The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing.

Participants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.

Read the detailed description

This study will enroll patients with a diagnosis of Synovial Sarcoma.

Following consent, demographic, clinical, treatment and outcome data will be collected from an interview and/or online survey. This will include a request for contact information for the subject's treating hospitals/physicians and a release of records request to obtain medical records.

At approximately 6-12 month intervals for up to 10 years after initial diagnosis and/or relapse, subjects and/or their treating hospitals may be contacted to provide updates on treatment and outcomes.

Tumor samples may be collected from residual material obtained during clinically indicated procedures occurring before or after consent to this study. No additional material will be collected or procedures performed solely for the purpose of this study.

Blood may be collected at the participant's local institution at the time of a clinically indicated blood draw and/or saliva or a buccal swab may be collected as a germline sample and for analysis of circulating free DNA (cfDNA) and/or circulating tumor cells (CTCs).

Genetic testing may be performed on tumor and germline samples submitted by subjects. Results will only be returned if deemed clinically significant.

02

Conditions studied

  • Synovial Sarcoma

Keywords

  • registry
  • biorepository
  • sarcoma
  • oncology
  • cancer
  • rare tumor
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males and females of any age with a reported diagnoses of synovial sarcoma.

Inclusion criteria

  1. Males or females of any age
  2. Reported diagnosis of synovial sarcoma
  3. Informed consent from subject (aged ≥18 years) or parent/guardian

Exclusion criteria

Exclusion Criteria:

  1. Individuals with sarcomas that do not fit the definition of those considered for this registry
  2. Individuals who are unwilling to participate
  3. Individuals who are unwilling or unable to provide written consent
04

Study design

Observational model
Other
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
05

What researchers measure

Primary outcomes

  1. Number of patients with synovial sarcoma

    Number of patients with synovial sarcoma

    Time frame: Up to 10 years

06

Study locations

1 of 1 sites recruiting
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — De-identified data and specimens may be provided to other investigators for additional research use. Identifiable data will only be available to the study team.

Supporting information: Study protocol, Icf

08

Registry details

Key details

Study ID
NCT05910307
Lead sponsor
Children's Hospital of Philadelphia
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jun 12, 2023
Primary completion
Jun 2028 (estimated)
Completion
Jun 2033 (estimated)
Last update
Jun 9, 2026

Study contacts

Lauren Gutstein
Contact
gutsteinl1@chop.edu
267-425-2029
James Robinson
Contact
robinsonj9@chop.edu
215-590-2053
Theodore Laetsch, MD
principal investigator · Children's Hospital of Philadelphia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion